Company intelligence / Profile preview

Sugarlogix

Berkeley, California, USA

Ownership: Private
Development stage: Other

Overview

Sugarlogix is a biotechnology company specializing in the production of Human Milk Oligosaccharides (HMOs) through advanced yeast fermentation technology. Originally focused on enhancing infant formula to more closely mimic human breast milk, the company expanded its applications to adult gut health and functional foods. Their platform enables the scalable and cost-effective synthesis of complex sugars like 2-fucosyllactose (2-FL), which support a healthy microbiome and immune system. In 2020, the company was acquired by Royal DSM to bolster its specialized health and nutrition portfolio.

Therapeutic areas: Metabolic DisordersGastroenterology
Modalities: BiologicPrebiotics
Industry: Non-Drug Biotech

Partnerships

Royal DSM

Beyond the preview

Go deeper on Sugarlogix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sugarlogix.

Explore the full profile